Hypersensitivity reactions to carboplatinand paclitaxel – our five-years experiences

Authors: A. Řezáč 1;  P. Jílek 2;  V. Řezáčová 3;  P. Škapinec 1;  I. Sedláková 1;  J. Tošner 1;  J. Špaček 1
Authors‘ workplace: Gynekologicko-porodnická klinika LF UK a FN, Hradec Králové, přednosta doc. MUDr. J. Špaček, Ph. D., IFEPAG 1;  Katedra biologických a lékařských věd, Farmaceutická fakulta LF UK, Hradec Králové, vedoucí katedry doc. PharmDr. P. Nachtigal, Ph. D. 2;  Ústav klinické imunologie a alergologie FN, Hradec Králové, přednosta prof. RNDr. J. Krejsek, CSc. 3
Published in: Čes. Gynek.2013, 78, č. 6 s. 514-521
Category: Original Article


To analyze hypersensitivity reactions to carboplatin and paclitaxel in patients treated with systemic administration of chemotherapy (carboplatin and/or paclitaxel).

Retrospective study.

Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove.

One hundred-forty patients treated with systemic administration of chemotherapy were enrolled to our study between years 2008 and 2012. The presence and the grade [grade (G) 1–5; 1 = moderate, 5 = death] of hypersensitivity reactions (HSRs) were evaluated, as well as the influence of some clinical parameters on development of HSR.

In total 29 HSRs in 21 patients were analyzed. To carboplatin were reported 19 (66%) HSRs: 13 (45%) HSRs of G1–G3 and 6 (21%) HSRs of G4. To paclitaxel were reported 10 (34%) HSRs: 9 (31%) HSRs of G1–G3 and 1 (3%) HSR of G4. The number of administered cycles of carboplatin to develop G1–G4 resp. G1–G3 HSR was higher in comparison with number of cycles to develop HSR of the same grade to paclitaxel(p = 0.001, resp. p = 0.01).

HSR to carboplatin is unlike paclitaxel affected by the number of administered cycles. This fact should be included in the clinical management of patients treated with intravenous chemotherapy using carboplatin.

chemotherapy – allergic reaction – ovarian cancer


1. Adkinson, NF. Drug allergy, allergy: principles practice, sixth ed., 2003, p. 1679–1694.

2. Ardavanis, A., Tryfonopoulos, D., Yiotis, I., et al. Non-allergic nature of docetaxel-induced acute hypersenzitivity reactions. Anticancer Drugs, 2004, 6, 15, p. 581–585.

3. Bois, A., Lück, HJ., Meier, W., et al. A randomized clinical trial of cisplatin/PACLI versus carboplatin/PACLI as first-line treatment of ovarian cancer. J Natl Cancer Inst, 2003, 17, 95, p. 1320–1329.

4. Castells, MC., Tennant, NM., Sloane, DE., et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. Clin Immunol, 2008, 122, p. 574–580.

5. Dizon, DS., Sabbatini, PJ., Aghajanian, C., et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynec Oncol, 2002, 3, 84 p. 378–382.

6. Goldberg, A., Confino-Cohen, R., Fishman, A., et al. A modified prolonged desensitization protocol in carboplatin allergy.J Allergy Clin Immunol, 1996, 98, p. 841–843.

7. González, ID., Saez, RS., Rodilla, EM., et al. Hypersensitivity reactions to chemotherapy drugs. Alergol Immunol Clin, 2000, 15, p. 161–181.

8. Halloy, JC. Use of Basophil activation test in a case of oxaliplatin hypersenzitivity. J Aller Ther, 2011, 1, 2, p. 2–3.

9. Iwamoto, T., Yuta, A., Tabata, T., et al. Evaluation of basophil CD203c as a predictor of carboplatin–related hypersenzitivityreaction in patiens with gynecologic cancer. Biol Pharm Bull, 2012, 9, 35, p. 1487–1495.

10. Kintzel, PE. Prophylaxis for PACLI hypersenzitivity reactions. Ann Pharmacother, 2001, 9, 35, p. 1114–1117.

11. Koshiba, H., Hosokawa, K., Kubo, A., et al. Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer, 2009, 6, 19, p. 1153.

12. Krejsek, J., Kopecký, O. Klinická imunologie. Hradec Kráolové: Nucleus HK, 2004, s. 649–679.

13. Lee, CW., Matulonis, UA., Castells, MC. Carboplatin hypersenzitivity: a 6-h 12-step protokol effective in 35 desensitizations in patiens with gynecological malignancies and mast cell/IgE - mediated reactions. Gynec Oncol, 2004, 2, 95, p. 370–376.

14. Leguy-Seguin, V., Jolimoy, G., Coudert, B., et al. Diagnostic and predictive value of skin testing in platinum salt hypersenzitivity. J Allergy Clin Immunol, 2007, 119, p. 726–730.

15. Markman, M., Hsieh, F., Zanotti, K. et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol, 2004, 1, 130, p. 25–28.

16. Markman, M., Kennedy, A., Webster, K., et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol, 1999, 17, p. 1141–1145.

17. Markman, M., Kennedy, A., Webster, K., et al. PACLI-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.J Clin Oncol, 2000, 1, 18, p. 102–105.

18. Markman, M., Zanotti, K., Peterson, G., et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersenzitivity. J Clin Oncol, 2003, 24, 21, p. 4611–4614.

19. Pagani, M., Venemalm, L., Bonnadona, P., et al. An experimental biological test to diagnose hypersenzitivity reactions to carboplatin: New horizont for an old problem. Jpn J Clin Oncol, 2012, 42, 4, p. 347–350.

20. Polyzos, A., Tsavaris, N., Kosmas, C., et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: A 10-year experience. Oncology, 2001, 61, p. 129–133.

21. Robinson, JB., Singh, D., Bodurka-Bevers, DC., et al. Hypersenzitivity reactions and the utility of oral and intravenous desensitization in patiens with gynecologic malignancies. Gynecol Oncol, 2001, 82, p. 550–558.

22. Rose, PG., Fusco, N., Smrekar, M., et al. Successful administration of carboplatin in patients with clinically documented carboplatin hypersenzitivity. Gynecol Oncol, 2003, 89, p. 429–433.

23. Santini, D., Tonini, G., Salermo, A., et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol, 2001, 12, p. 132–133.

24. Shepherd, GM. Hypersensitivity reactions to chemothera-peutic drugs. Clin Rev in Allergy and Immunology, 2003, 24, p. 253–262.

25. Schnyder, B., Pichler, WJ. Mechanisms of drug-induced allergy. Mayo Clin. Proc., 2009, 3, 84, p. 268–272.

26. Schwartz, JR., Bandera, C., Bradley, A., et al. Does the platinum-free interval predict the incidence or severity of hypersenzitivity reactions to carboplatin? The exprience from Women and infants´ Hospital. Gynecol Oncol, 2007, 1, 105, p. 81–83.

27. Solesky, R., Khan, DA. Drug allergy: an updated practice parameter. Ann Allergy, Asthma Immunol, 2010, 105, p. 1–76.

28. Thomas, RR., Quinn, MG., Schuler, B., et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 2003, 97, p. 2301–2307.

29. Tran, NP., Katcher, J., Rohman, E., et al. Vancomycin hypersenzitivity diagnosed by lymfocyte blast transforamation. Pediatrics, 2011, p. 3.

30. Zanotti, KM., Markman, M. Prevention and management of antineoplastic-induced hypersenzitivity reactions. Drug Saf, 2001, 24, p. 767–779.

31. Zanotti, KM., Rybicki, LA., Kennedy, AW., et al. Carboplatin skin testing: a skin-testing protokol for predicting hypersenzitivity to karboplatin chemotherapy. J Clin Oncol, 2001, 12, 19, p. 3126–3129.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine

Article was published in

Czech Gynaecology

Issue 6

2013 Issue 6

Most read in this issue

This topic is also in:

Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account